An exterior view of PharmaMax Pharmaceuticals. [Photo/WeChat account: weigg6666]
The Investigational New Drug (IND) application for PC-0120, an innovative drug independently developed by PharmaMax Pharmaceuticals, located in the Taizhou Medical High-tech Zone in Taizhou, Jiangsu province, has been accepted by the National Medical Products Administration.
PC-0120 tablets are the cornerstone of PharmaMax's research and development pipeline for anti-tumor treatments, mainly used for the treatment of acute myeloid leukemia (AML).
Compared to similar drugs already on the market, PC-0120 tablets are designed to reduce blood toxicity, offering patients a safer and milder treatment option.
Since the settlement in 2010, PharmaMax has focused on self-innovation and iterative optimization, constantly addressing key technological challenges in the core areas of spirit, respiration and oncology.
To date, the company has laid out more than 30 product pipelines and secured nearly 120 national patents.